http://web.archive.org/web/20131018001954id_/http://www.dailymail.co.uk/health/article-2465570/New-prostate-cancer-drug-approved-use-NHS-offers-month-lifeline.html

by @entity0 published : 19:13 est , 17 october 2013 updated : 19:13 est , 17 october 2013 access denied : @entity2 could benefit 1,000 patients a year but is deemed to lack evidence of benefits a drug for prostate cancer victims who have run out of other treatment options has been approved for use on the @entity11			1
@entity12 extends life by at least five months for men who have stopped responding to hormone treatments or chemotherapy			1
doctors hope the substance – developed in the @entity19 – will help turn prostate cancer from a killer disease into a chronic illness with much longer survival rates			0
trials show men taking the drug lived for five months longer than they would have done , with almost half having a better quality of life as a result			1
around 10,500 @entity30 men have advanced prostate cancer that has become resistant to standard hormone treatments			0
the new drug , which is a pill taken at home , costs around £ 25,000 for an average course of treatment			0
but the manufacturer @entity37 has cut the price through a patient access scheme which makes it cost - effective , according to the @entity40 , the @entity11 rationing body			1
the drug was created by @entity30 scientists at the @entity44 ( @entity44 ) and the @entity45 , @entity46			0
professor @entity47 , chief executive of the @entity44 said : ‘ advanced prostate cancer is very difficult to treat , and it ’s taken a co-ordinated effort to finally bring new drugs into the pipeline , after decades where there were no options once old - style hormone treatment stopped working			0
‘ what we ’re seeing now is an unprecedented period of success for prostate cancer research , with four new drugs shown to extend life in major clinical trials in just two years , and several others showing promise			1
‘ it truly is a golden age for prostate cancer drug discovery and development			0
’ @entity12 was assessed in 1,199 patients with advanced prostate cancer who had previously received chemotherapy			2
survival with enzalutamide was 18.4 months on average , compared with 13.6 months for men receiving a placebo			1
killer : prostate cancer , pictured here under a microscope , killed men within 14 months without the new drug around 43 per cent of men taking the pill reported an improved quality of life , compared with 18 per cent of men taking a placebo , says a report in the @entity91			1
the trial went so well that an independent monitoring committee recommended it be stopped early in november last year so the men who received the placebo could be offered enzalutamide			2
in november last year , the trial ’s @entity97 recommended the trial be stopped early and men who received the placebo be offered enzalutamide			2
@entity102 , of @entity19 , said : ‘ this is great news for men … we need clinicians to have options at their disposal to do what counts – extend the lives of men with this disease when other options have run out			0
’ he added : ‘ the truth is that there are precious few treatments for a condition which not only seriously impinges upon the life of those with advanced disease , but kills one man each hour			2
this is a victory for these men today			0
professor @entity123 , of the @entity124 at @entity40 , said : ‘ there are few treatments available for patients at this stage in their cancer so we are very pleased that we are able to produce draft guidance recommending enzalutamide			0
’ the drug is expected to become available on the @entity11 in @entity133 early next year .			1

@entity12 was approved by the @entity11 rationing body after a price cut
in trials it boosted life *expectancy* from 13.6 months to 18.4 months
it also *increased* quality of life in half of those suffering the *deadly* disease
the drug is expected to become available early next year

@entity2:Crizotinib
@entity0:Jenny Hope
@entity12:Enzalutamide
@entity11:NHS
@entity30:British
@entity46:London
@entity19:Prostate Cancer UK
@entity44:ICR
@entity37:Astellas Pharma
@entity45:Royal Marsden Hospital
@entity102:Owen Sharp
@entity47:Alan Ashworth
@entity40:Nice
@entity91:New England Journal of Medicine
@entity97:Independent Data Monitoring Committee
@entity124:Centre for Health Technology Evaluation
@entity123:Carole Longson
@entity133:England